These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 32275654)

  • 1. Pre-exposure prophylaxis for preventing acquisition of HIV: A cross-sectional study of patients, prescribers, uptake, and spending in the United States, 2015-2016.
    Chan SS; Chappel AR; Maddox KEJ; Hoover KW; Huang YA; Zhu W; Cohen SM; Klein PW; De Lew N
    PLoS Med; 2020 Apr; 17(4):e1003072. PubMed ID: 32275654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National Trends in Drug Payments for HIV Preexposure Prophylaxis in the United States, 2014 to 2018 : A Retrospective Cohort Study.
    Furukawa NW; Zhu W; Huang YA; Shrestha RK; Hoover KW
    Ann Intern Med; 2020 Nov; 173(10):799-805. PubMed ID: 32894696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States.
    Siegler AJ; Mouhanna F; Giler RM; Weiss K; Pembleton E; Guest J; Jones J; Castel A; Yeung H; Kramer M; McCallister S; Sullivan PS
    Ann Epidemiol; 2018 Dec; 28(12):841-849. PubMed ID: 29983236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uptake of HIV Preexposure Prophylaxis Among Commercially Insured Persons-United States, 2010-2014.
    Wu H; Mendoza MC; Huang YA; Hayes T; Smith DK; Hoover KW
    Clin Infect Dis; 2017 Jan; 64(2):144-149. PubMed ID: 27986691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV Care Providers' Intentions to Prescribe and Actual Prescription of Pre-Exposure Prophylaxis to At-Risk Adolescents and Adults.
    Mullins TLK; Zimet G; Lally M; Xu J; Thornton S; Kahn JA
    AIDS Patient Care STDS; 2017 Dec; 31(12):504-516. PubMed ID: 29211514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Barriers to the Wider Use of Pre-exposure Prophylaxis in the United States: A Narrative Review.
    Mayer KH; Agwu A; Malebranche D
    Adv Ther; 2020 May; 37(5):1778-1811. PubMed ID: 32232664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vital Signs: Increased Medicaid Prescriptions for Preexposure Prophylaxis Against HIV infection--New York, 2012-2015.
    Laufer FN; O'Connell DA; Feldman I; ; Zucker HA
    MMWR Morb Mortal Wkly Rep; 2015 Nov; 64(46):1296-301. PubMed ID: 26606257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mind the gaps: prescription coverage and HIV incidence among patients receiving pre-exposure prophylaxis from a large federally qualified health center in Los Angeles, California : Mind the Gaps: Cobertura de recetas e incidencia de VIH entre pacientes recibiendo profilaxis pre-exposición de un centro de salud grande y federalmente calificado en Los Ángeles, CA.
    Shover CL; Shoptaw S; Javanbakht M; Lee SJ; Bolan RK; Cunningham NJ; Beymer MR; DeVost MA; Gorbach PM
    AIDS Behav; 2019 Oct; 23(10):2730-2740. PubMed ID: 30953305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brief Report: HIV Pre-exposure Prophylaxis Prescribing in an Urban Safety-Net Health System.
    Agovi AM; Anikpo I; Cvitanovich MJ; Fasanmi EO; Ojha RP; Marcus JL
    J Acquir Immune Defic Syndr; 2021 Nov; 88(3):e17-e21. PubMed ID: 34285157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial.
    Zablotska IB; Selvey C; Guy R; Price K; Holden J; Schmidt HM; McNulty A; Smith D; Jin F; Amin J; Cooper DA; Grulich AE;
    BMC Public Health; 2018 Feb; 18(1):210. PubMed ID: 29394918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017.
    Sullivan PS; Giler RM; Mouhanna F; Pembleton ES; Guest JL; Jones J; Castel AD; Yeung H; Kramer M; McCallister S; Siegler AJ
    Ann Epidemiol; 2018 Dec; 28(12):833-840. PubMed ID: 30037634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are We Hitting the Target? HIV Pre-Exposure Prophylaxis from 2012 to 2020 in the OPERA Cohort.
    Mounzer KC; Fusco JS; Hsu RK; Brunet L; Vannappagari V; Frost KR; Shaefer MS; Rinehart A; Rawlings K; Fusco GP
    AIDS Patient Care STDS; 2021 Nov; 35(11):419-427. PubMed ID: 34609897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimated Coverage to Address Financial Barriers to HIV Preexposure Prophylaxis Among Persons With Indications for Its Use, United States, 2015.
    Smith DK; Van Handel M; Huggins R
    J Acquir Immune Defic Syndr; 2017 Dec; 76(5):465-472. PubMed ID: 28834798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV Preexposure Prophylaxis, by Race and Ethnicity - United States, 2014-2016.
    Huang YA; Zhu W; Smith DK; Harris N; Hoover KW
    MMWR Morb Mortal Wkly Rep; 2018 Oct; 67(41):1147-1150. PubMed ID: 30335734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vital Signs: Estimated Percentages and Numbers of Adults with Indications for Preexposure Prophylaxis to Prevent HIV Acquisition--United States, 2015.
    Smith DK; Van Handel M; Wolitski RJ; Stryker JE; Hall HI; Prejean J; Koenig LJ; Valleroy LA
    MMWR Morb Mortal Wkly Rep; 2015 Nov; 64(46):1291-5. PubMed ID: 26606148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perceived HIV Acquisition Risk and Low Uptake of PrEP Among a Cohort of Transgender Women With PrEP Indication in the Eastern and Southern United States.
    Malone J; Reisner SL; Cooney EE; Poteat T; Cannon CM; Schneider JS; Radix A; Mayer KH; Haw JS; Althoff KN; Wawrzyniak AJ; Beyrer C; Wirtz AL;
    J Acquir Immune Defic Syndr; 2021 Sep; 88(1):10-18. PubMed ID: 34397742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methods for county-level estimation of pre-exposure prophylaxis coverage and application to the U.S. Ending the HIV Epidemic jurisdictions.
    Sullivan PS; Mouhanna F; Mera R; Pembleton E; Castel AD; Jaggi C; Jones J; Kramer MR; McGuinness P; McCallister S; Siegler AJ
    Ann Epidemiol; 2020 Apr; 44():16-30. PubMed ID: 32088073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Awareness of, interest in, and willingness to pay for HIV pre-exposure prophylaxis among Canadian gay, bisexual, and other men who have sex with men.
    Morgan J; Ferlatte O; Salway T; Wilton J; Hull M
    Can J Public Health; 2018 Dec; 109(5-6):791-799. PubMed ID: 29981103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of new HIV diagnosis rates among high-risk, PrEP-eligible individuals using HIV surveillance data at the Metropolitan Statistical Area level in the United States.
    Mera R; Scheer S; Carter C; Das M; Asubonteng J; McCallister S; Baeten J
    J Int AIDS Soc; 2019 Dec; 22(12):e25433. PubMed ID: 31860171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
    Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K
    PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.